Targeting menin induces responses in acute leukemias with KMT2A...
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as...
Study discovers triple immunotherapy combination as...
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting...
Sotorasib shows clinically meaningful activity in KRAS...
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable...
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
Novel drug combinations and targeted therapies show promise...
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at...
MD Anderson Research Highlights: ASH 2022 Special Edition
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides...
MD Anderson’s Christopher Flowers, M.D., receives ASH...
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD...
MD Anderson Research Highlights: SABCS 2022 Special Edition
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...